Alcobra Ltd. Ord (ADHD) 4.77 $ADHD Alcobra Ltd. to

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2016 at 12:18 AM

Alcobra Ltd. Ord (ADHD) 4.77 $ADHD

Alcobra Ltd. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
GlobeNewswire - Tue Jul 05, 7:00AM CDT
Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced that it will be presenting at the upcoming Cantor Fitzgerald 2 Annual Healthcare Conference.
ADHD: 4.77 (-0.09)

Alcobra Ltd. to Participate in Upcoming Investment Conferences
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3 Annual Healthcare Day.
ADHD: 4.77 (-0.09)

Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:30AM CDT
Alcobra Ltd (ADHD) was a big mover last session, as the company saw its shares rise over 6% on the day.
ADHD: 4.77 (-0.09), JNP: 7.70 (-0.19)

The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
Zacks Equity Research - Zacks Investment Research - Mon May 16, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
SNDX: 10.59 (-0.23), EDIT: 25.24 (-0.08), ADHD: 4.77 (-0.09), MCRB: 30.51 (+0.52), NEOS: 9.31 (-0.06)

Alcobra reports 1Q loss
Automated Insights - Mon May 16, 7:15AM CDT
TEL AVIV, Israel (AP) _ Alcobra Ltd. (ADHD) on Monday reported a loss of $5.1 million in its first quarter.
ADHD: 4.77 (-0.09)

Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 16, 7:00AM CDT
-- Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 4.77 (-0.09)

Drug Stocks' Earnings to Watch on May 16: ADHD, MCRB & More
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:26AM CDT
What's in store for drug stocks, Alcobra, Seres and others when they report their first-quarter results on May 16?
SNDX: 10.59 (-0.23), EDIT: 25.24 (-0.08), ADHD: 4.77 (-0.09), MCRB: 30.51 (+0.52), NEOS: 9.31 (-0.06)

Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16
GlobeNewswire - Wed May 04, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
ADHD: 4.77 (-0.09)

MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.77 (-0.09), MEIP: 1.39 (-0.02)

Falling Earnings Estimates Signal Weakness Ahead for Valeant Pharmaceuticals (VRX)
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:53AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
VRX: 23.09 (-0.16), ADHD: 4.77 (-0.09)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.77 (-0.09), REPH: 7.73 (-0.22)

What Falling Estimates & Price Mean for Lannett (LCI)
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:40AM CDT
Lannett has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
LCI: 27.72 (+3.13), ADHD: 4.77 (-0.09)

Alcobra (ADHD) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:34AM CDT
Alcobra Ltd. (ADHD) has been struggling lately, but the selling pressure may be coming to an end soon
ADHD: 4.77 (-0.09)

Grab These 4 Incredible Momentum Stocks for Less Than $10
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 9:10AM CDT
Momentum investing grants success to those who can effectively ride the upswing and brave the downswing of the market with the same elan.
PRMW: 11.55 (+0.09), ADHD: 4.77 (-0.09), VSLR: 2.84 (+0.02), MDXG: 8.17 (-0.08)

Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.77 (-0.09), OHRP: 2.72 (+0.02)

AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 2.96 (-0.02), GILD: 86.25 (-0.30), ADHD: 4.77 (-0.09)

Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 4.14 (+0.02), ADHD: 4.77 (-0.09)

Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 4.77 (-0.09), ANAC: 99.06 (-0.14)

What's in Store for Penumbra (PEN) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:20PM CST
Penumbra, Inc. (PEN) is expected to report its fourth-quarter and full year 2015 financial numbers on Feb 11, after the market close.
VWR: 29.38 (+0.12), ADHD: 4.77 (-0.09), PEN: 60.71 (+0.22), MGLN: 67.54 (+0.24)

GNC Holdings (GNC) Q4 Earnings: A Turnaround in Store?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 11:50AM CST
The combination of GNC Holdings' (GNC) Zacks Rank #3 and +1.67% ESP makes us confident of a positive earnings beat at the company.
CNC: 71.60 (+0.67), ADHD: 4.77 (-0.09), GNC: 25.75 (+0.22), MGLN: 67.54 (+0.24)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Giese Foundation Boosts Cancer Support Services Reach

When cancer pays an unwelcome visit to a family, it doesn’t come alone. It drags along fear, uncertainty, and bruising challenges. And as support needs balloon, thankfully there's a beacon like the Brian & Patricia Giese Foundation stepping up to sustain vital programs. Understanding the Real Impact Now, listen up. Cancer may target one body, but its claws reach...

Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

InfraMed Expands Team for National Healthcare Growth

InfraMed's Bold Move in Healthcare Real Estate You know, it’s not every day you see a company go all in on healthcare properties like InfraMed’s doing. With the blitz of new personnel, we're talking about a genuine push to carve out a piece of the national market. And if you've been keeping tabs, this isn't just a hunch—they've got serious momentum brewing, and the...

Roofr Unveils AI Tools: Shaping Roofing's Future

Making Waves in Roofing: Roofr's Big Moves Listen up, folks. When a company like Roofr announces new tech, contractors better pay attention. The roofing industry—often overlooked by the flashy tech scene—just got hit with some slick new tools. Today, Roofr held its semi-annual virtual event, Roofr Builds, unraveling a slew of updates that might just streamline the way...

Escalade to Unveil Q3 2026 Results and Host Call

Details on Escalade's Upcoming Financial Revelation Evansville's own Escalade, Inc. (NASDAQ: ESCA) is set to drop its third quarter 2026 financial results on October 29, well before your breakfast is done. For anyone following this stock, it's like waiting for the last few seconds of a tied basketball game. This isn’t just about numbers – it’s about a whole host of...

Green Builder Media's Fresh Focus on Net Zero Homes

There's a fresh breeze blowing through the building industry, and it's got "net zero" written all over it. Green Builder Media is rolling out a pile of new resources aimed at wrangling this beast of a trend. The focus? High-performance, all-electric homes. And they're not just whispering about it—they've got hard data and practical guidance to back up their claims. Net...

OTconnect on Apple Watch: A New Fitness Era Dawns

What’s Orangetheory Up To Now? Ah, fitness gadgets, where everyone’s seemingly got a scheme brewing. This time it's Orangetheory (OTF), turning your Apple Watch into your new best gym buddy. October 22, 2026, marks the launch of OTconnect for Apple Watch, offering a slick way for enthusiasts to tune into their own sweat metrics. If you’re already an Apple Watch...

US Myeloma Network Revolutionizes Cancer Trials in U.S.

New Era for Myeloma Research In a move set to shake up the oncology world, the International Myeloma Foundation (IMF) is lighting a fire under clinical research with its ambitious US Myeloma Network (USMN). The whole shebang is about supercharging clinical trials and bringing real hope to folks battling multiple myeloma. If you've been watching the space, you know we're...

Rising Demand for Natural Fibres: Woolmark's Bold Move

A Shift Toward Nature-Driven Choices There's something brewing in the fashion world that signals a deeper shift—a movement toward fibers that feel real, fibers that nature and time have refined. Recent Ipsos research commissioned by Woolmark has laid bare the growing consumer preference across major markets, with a distinct swing towards natural fibers, leaving...

Fort Point Capital Sells AMS Fulfillment to Stord

Fort Point Capital's Strategic Play Just when you thought the game was getting stale, Fort Point Capital dropped a bomb: they’ve sold AMS Fulfillment to Stord. This isn't just some late-season punt; it's a calculated play from a Boston-based private equity player known for snapping up and scaling service-oriented businesses in the lower middle market. It's like...